The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Alterations in DNA-damage repair (DDR) pathways occur in approximately 20% of prostate cancer patients.
• These alterations are linked to enhanced sensitivity to poly(ADP ribose) polymerases (PARP) inhibitors, a class of drugs recently approved for prostate cancer treatment.
• Germline aberrations in DDR genes are associated with hereditary prostate cancer, necessitating specialized healthcare.

Purpose of the Study:

• To provide a comprehensive overview of DDR pathways in prostate cancer.
• To address key questions regarding the rationale for targeting DDR, genomic profiling, testing strategies, and patient selection for PARP inhibitors.
• To explore combination strategies for improving patient outcomes.

Main Methods:

• Review of current literature on DNA-damage repair pathways in prostate cancer.
• Analysis of genomic profiling and genetic testing approaches (germline, somatic, solid, liquid biopsy).
• Discussion of clinical guidelines and emerging therapeutic strategies, including PARP inhibitors and combination therapies.

Main Results:

• DDR pathway alterations are a significant biomarker in prostate cancer, influencing treatment response.
• Genomic profiling is crucial for identifying patients eligible for PARP inhibitor therapy.
• Germline testing is important for managing hereditary prostate cancer cases.

Conclusions:

• Targeting DDR pathways represents a paradigm shift in prostate cancer management.
• Personalized therapeutic strategies based on DDR status are essential.
• Further research into combination therapies holds promise for improving patient outcomes in prostate cancer.